UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
UroGen Pharma (Nasdaq: URGN), a biotech company focused on urothelial and specialty cancer treatments, has announced its participation in an upcoming fireside chat at the TD Cowen 45th Annual Health Care Conference. The conference is scheduled for March 3-5, 2025.
The company will make webcasts of the conference presentations available on their Investor Relations website, with replays accessible for approximately 90 days following the event.
UroGen Pharma (Nasdaq: URGN), una azienda biotech focalizzata sui trattamenti per il cancro uroteliale e specializzato, ha annunciato la sua partecipazione a un prossimo incontro informale al 45° Annual Health Care Conference di TD Cowen. La conferenza è programmata per dal 3 al 5 marzo 2025.
L'azienda metterà a disposizione le registrazioni delle presentazioni della conferenza sul proprio sito web per le relazioni con gli investitori, con la possibilità di rivederle per circa 90 giorni dopo l'evento.
UroGen Pharma (Nasdaq: URGN), una empresa biotecnológica centrada en tratamientos para el cáncer urotelial y especializado, ha anunciado su participación en una próxima charla informal en la 45ª Conferencia Anual de Atención Médica de TD Cowen. La conferencia está programada para del 3 al 5 de marzo de 2025.
La empresa hará disponibles las grabaciones de las presentaciones de la conferencia en su sitio web de Relaciones con Inversores, con repeticiones accesibles durante aproximadamente 90 días después del evento.
UroGen Pharma (Nasdaq: URGN)는 요로 상피 및 특수 암 치료에 집중하는 생명공학 회사로, TD Cowen 제45회 연례 건강 관리 회의에서 열릴 예정인 화상 대화에 참여한다고 발표했습니다. 회의는 2025년 3월 3일부터 5일까지 예정되어 있습니다.
회사의 투자자 관계 웹사이트에서 회의 발표의 웹캐스트를 제공하며, 이벤트 후 약 90일 동안 다시 볼 수 있습니다.
UroGen Pharma (Nasdaq: URGN), une entreprise biopharmaceutique spécialisée dans les traitements du cancer urotélial et spécialisé, a annoncé sa participation à une prochaine discussion informelle lors de la 45e Conférence Annuelle sur les Soins de Santé de TD Cowen. La conférence est prévue pour du 3 au 5 mars 2025.
L'entreprise mettra à disposition des webcasts des présentations de la conférence sur son site Web des Relations avec les Investisseurs, avec des rediffusions accessibles pendant environ 90 jours après l'événement.
UroGen Pharma (Nasdaq: URGN), ein Biotech-Unternehmen, das sich auf uroteliale und spezialisierte Krebstherapien konzentriert, hat seine Teilnahme an einem bevorstehenden Fireside-Chat auf der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Die Konferenz ist für vom 3. bis 5. März 2025 angesetzt.
Das Unternehmen wird die Webcasts der Konferenzpräsentationen auf seiner Investor-Relations-Website zur Verfügung stellen, wobei die Wiederholungen etwa 90 Tage nach der Veranstaltung zugänglich sind.
- None.
- None.
TD Cowen 45th Annual Health Care Conference
Date / Time: |
March 3, 2025 at 1:50 PM ET |
Format: |
Presentation and 1x1 investor meetings |
Location: |
|
Webcast Link: |
Webcasts from the conferences will also be available on UroGen’s Investor Relations website. A replay will be available on the site for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat LG-UTUC and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224504690/en/
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
Source: UroGen Pharma Ltd.
FAQ
When is UroGen Pharma (URGN) presenting at the TD Cowen Healthcare Conference 2025?
How long will the URGN TD Cowen conference webcast be available for replay?
What type of presentation will URGN give at the TD Cowen Healthcare Conference 2025?
Where can investors watch UroGen's (URGN) TD Cowen conference presentation?
What is UroGen Pharma's (URGN) main business focus?
